Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion–Mutated Breast Cancer
Year: 2023
Type: article
Study design: Case Report
Source: JCO Precision Oncology
DOI: 10.1200/po.23.00174
Authors: Sean R. O'Neil, Garrett A. Weber, Dustin A. Deming, Mark E. Burkard, Paraic A. Kenny, Craig S. Richmond, Benjamin M. Parsons
Institutions: Gundersen Health System, University of Wisconsin–Madison
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4385190815